期刊
BIOMED RESEARCH INTERNATIONAL
卷 2013, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2013/726375
关键词
-
资金
- Chinese National Foundation of National Sciences [81270036]
- Science and Technology Project of Liaoning Province [20114040135]
- National Science and Technology Major Project [2010ZX09401-304-110G, LJQ2011082]
Epidermal growth factor receptor (EGFR) is one of the most promising targets for non-small-cell lung cancer (NSCLC). Icotinib, a highly selective EGFR tyrosine kinase inhibitor (EGFR-TKI), has shown promising clinical efficacy and safety in patients with NSCLC. The exact molecular mechanism of icotinib remains unclear. In this study, we first investigated the antiproliferative effect of icotinib on NSCLC cells. Icotinib significantly inhibited proliferation of the EGFR-mutated lung cancer HCC827 cells. The IC 50 values at 48 and 72 h were 0.67 and 0.07 mu M, respectively. Flow cytometric analysis showed that icotinib caused the G1 phase arrest and increased the rate of apoptosis in HCC827 cells. The levels of cyclin D1 and cyclin A2 were decreased. The apoptotic process was associated with activation of caspase-3, -8, and poly(ADP-ribose) polymerase (PARP). Further study revealed that icotinib inhibited phosphorylation of EGFR, Akt, and extracellular signal-regulated kinase. In addition, icotinib upregulated ubiquitin ligase Cbl-b expression. These observations suggest that icotinib-induced upregulation of Cbl-b is responsible, at least in part, for the antitumor effect of icotinib via the inhibition of phosphoinositide 3-kinase(PI3K)/Akt and mitogen-activated protein kinase pathways in EGFR-mutated NSCLC cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据